Response 1 to pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: A critical appraisal

British Journal of Dermatology

Volumn 166, Issue 1, 2012, Pages 11-12

  Shen, C Y ^a   Chen, Y T ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; HLA B ANTIGEN;

COST EFFECTIVENESS ANALYSIS; FOLLOW UP; GENETIC SCREENING; GENOTYPE; HUMAN; INCIDENCE; NOTE; PHARMACOGENETICS; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 84555190179     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10759.x     Document Type: Note

References (2)

1. Wu K, Reynolds NJ,. Pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal. Br J Dermatol 2012; 166: 7-11.
2. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364: 1126-33.